Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ABT-100 is a potent, highly selective, and orally active farnesyl transferase inhibitor with broad-spectrum antitumor activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 977.00 | |
50 mg | 6-8 weeks | $ 1,270.00 | |
100 mg | 6-8 weeks | $ 1,930.00 |
Description | ABT-100 is a potent, highly selective, and orally active farnesyl transferase inhibitor with broad-spectrum antitumor activity. |
In vitro | ABT-100 (0.1-100 nM; 7 days; EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells) treatment shows dose-dependent growth inhibition of human cancer cell lines. It also inhibits colony formation at concentrations comparable with which ABT-100 inhibits anchorage-dependent growth. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. |
In vivo | ABT-100 (6.25-12.5 mg/kg/day; subcutaneous injection; daily; for 21 days; C.B-17 scid male mice) treatment regresses EJ-1 tumors in mice. |
Cell Research | Cell Line: EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells. Concentration: 0.1-100 nM. Incubation Time: 7 days |
Animal Research | Animal Model: C.B-17 scid male mice with EJ-1 cells. Dosage: 6.25 mg/kg/day, 12.5 mg/kg/day. Administration: Subcutaneous injection; daily; for 21 days |
Molecular Weight | 504.46 |
Formula | C27H19F3N4O3 |
CAS No. | 450839-40-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ABT-100 450839-40-4 Others ABT100 ABT 100 inhibitor inhibit